Compass Therapeutics, Inc. (CMPX)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Thomas J. Schuetz M.D., Ph.D. | Chief Executive Officer | 835.88k | -- | 1961 |
| Ms. Vered Bisker-Leib MBA, Ph.D. | Advisor | 719k | -- | 1971 |
| Mr. Neil L. Lerner CPA | Vice President of Finance | -- | -- | 1967 |
| Mr. Jonathan Anderman J.D. | VP, Head of Legal & Corporate Secretary | -- | -- | -- |
| Anna Gifford | Communications Manager | -- | -- | -- |
| Dr. Minori Rosales M.D., Ph.D. | Senior VP & Head of Clinical Development | -- | -- | 1963 |
| Ms. Karin Herrera B.A. | VP & Head of Clinical Operations | -- | -- | -- |
| Dr. James Kranz Ph.D. | VP and Head of Chemistry Manufacturing & Controls | -- | -- | -- |
Compass Therapeutics, Inc.
- Sector:?
- Healthcare
- Industry:? Biotechnology
- Full Time Employees:?
- 32
Description
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
September 4, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission